Harvard Management Company’s Maze Therapeutics MAZE Stock Holding History

Harvard Management Company’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-92,396	Closed	-$2.4M	–	22
2025 Q3	$2.4M	Sell	92,396 -545,132	-86%	-$9.2M	0.11%	17
2025 Q2	$7.82M	Hold	637,528	–	–	0.54%	12
2025 Q1	$7.02M	Buy	+637,528	New	+$7.68M	0.62%	12

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Harvard Management Company's MAZE Position: Q4 2025 in Review

Harvard Management Company sold out of Maze Therapeutics (MAZE) in Q4 2025, closing a stake of 92,396 shares — an estimated $2.4M sold.

Harvard Management Company first reported a position in MAZE in Q1 2025 and held it in 3 quarters. The position peaked at $7.82M in Q2 2025. 143 funds tracked by Wall St. Rank hold MAZE as of Q4 2025.

Harvard Management Company reported no remaining Maze Therapeutics position as of Q4 2025 after selling out during the quarter.
Harvard Management Company sold 92,396 Maze Therapeutics shares in Q4 2025, an estimated $2.4M.
Harvard Management Company first reported a position in Maze Therapeutics in Q1 2025 and held it in 3 quarters.
Harvard Management Company's Maze Therapeutics position peaked at $7.82M in Q2 2025.
143 funds tracked by Wall St. Rank held Maze Therapeutics as of Q4 2025.

Based on Harvard Management Company's 13F filing for Q4 2025, filed 13 Feb 2026.